Author
@fwpharma fwpharma
Biopharma trade-press feed relaying FDA, clinical, M&A and earnings news in real time
FirstWord Pharma's account broadcasts comprehensive, first-p
trader score
-1.91
hit rate
25%
mean α
-0.87%
signals 14d
56
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 25% hit rate, -0.87% mean alpha, trader score -1.91. Their last-14d mentions, direction-adjusted, have moved +3.5% since posting (mean over 30 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | LLY | @fwpharma | +0.50 | Lilly's weight-loss pill received backing from an EU regulator. | +1.3% | tweet ↗ |
| 2026-10-16 | · | @fwpharma | · | Estuary launched with $103M to pursue gene therapy for kidney disease. | · | tweet ↗ |
| 2026-10-16 | CTY | @fwpharma | +0.20 | City raised $200M in an upsized IPO to advance RNAi therapies. | · | tweet ↗ |
| 2026-10-16 | RHHBY | @fwpharma | +0.50 | FDA cleared Roche's Enspryng as the first at-home thyroid eye disease therapy. | +7.1% | tweet ↗ |
| 2026-10-16 | · | @fwpharma | · | OrbiMed plans to invest $3B in healthcare across the US, Europe and Asia. | · | tweet ↗ |
| 2026-10-15 | IAM | @fwpharma | +0.20 | Iambic raised $150M through an IPO to advance its cancer pipeline. | · | tweet ↗ |
| 2026-10-15 | AZN | @fwpharma | +0.30 | AstraZeneca and insitro entered a $1.5B cardiometabolic drug-discovery deal. | +2.9% | tweet ↗ |
| 2026-10-15 | VNDA | @fwpharma | -0.50 | Vanda paused a social-anxiety program after a late-stage trial miss. | -5.4% | tweet ↗ |
| 2026-10-15 | · | @fwpharma | · | OMass raised $310M to advance an adrenal-disorder therapy. | · | tweet ↗ |
| 2026-10-14 | VIR | @fwpharma | +0.50 | Gilead and Vir entered a $1.9B T-cell-engager pact for solid tumors. | · | tweet ↗ |
| 2026-10-14 | GILD | @fwpharma | -0.10 | Gilead and Vir entered a $1.9B T-cell-engager pact for solid tumors. | +1.6% | tweet ↗ |
| 2026-10-14 | LQDA | @fwpharma | +0.20 | A settlement keeps Liquidia's Yutrepia on the market, though under a narrower label. | +25.7% | tweet ↗ |
| 2026-10-14 | GSK | @fwpharma | -0.20 | GSK plans to cut more than 1,200 Belgian jobs in a cost-saving drive. | +6.0% | tweet ↗ |
| 2026-10-14 | SNY | @fwpharma | -0.15 | Sanofi reportedly committed to remedy harm from a campaign against a rival flu shot. | +4.6% | tweet ↗ |
| 2026-10-14 | BNTX | @fwpharma | -0.60 | BioNTech's HPV-targeted cancer vaccine missed its progression-free-survival goal. | -0.6% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.